IVEVF (Inventiva) Quality Rank


IVEVF Inventiva SA IVEVF
34 GF Score
Price $3.59
GF Value $0.25
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Inventiva Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Inventiva Quality Rank Related Terms

IVEVF
34GF Score
Inventiva SA IVEVF
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Inventiva (IVEVF) Overvalued in 2026?

Based on GuruFocus' analysis, Inventiva stock appears to be overvalued. The current stock price of $3.59 is trading 1336% above its estimated GF Value™ of $0.25. GuruFocus considers Inventiva to be Significantly Overvalued.

Key valuation signals for IVEVF:

  • Quality Rank:
  • GF Value™: $0.25 vs. price of $3.59 (1336% above fair value)
  • GF Score™: 34/100 with 7 warning signs

No single metric tells the full story. See the IVEVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Inventiva Business Description

Address 50 rue de Dijon, Daix, FRA, 21121
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.
34GF Score

Get the complete analysis for IVEVF

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.59
Price
$0.25
GF Value